by ElasmoAdm1n | Jan 15, 2026 | News, Team
Dr Suhail Nurbhai is a highly accomplished physician-scientist, Dr Nurbhai brings deep expertise in advancing therapeutics from preclinical development through regulatory approval and into the clinic. His leadership will be instrumental as Elasmogen progresses its...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:Â Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:Â Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020: Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology. In April 2020...